CA2415544A1 - Compositions and methods for the therapy and diagnosis of lung cancer - Google Patents

Compositions and methods for the therapy and diagnosis of lung cancer Download PDF

Info

Publication number: CA2415544A1
Authority: CA; Canada
Prior art keywords: seq; clone; cdna sequence; determined cdna; sequence
Prior art date: 2000-07-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002415544A

Other languages

English (en)

French (fr)

Inventor

Tongtong Wang

Yoshihiro Watanabe

Robert A. Henderson

Jeffrey C. Johnson

Marc W. Retter

Margarita Durham

Darrick Carter

Gary Richard Fanger

Thomas S. Vedvick

Chaitanya S. Bangur

Andria Mcnabb

Aijun Wang

Neil Fanger

Ann Switzer

Patricia D. Mcneill

Jonathan D. Clapper

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Corixa Corp

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-11

Filing date

2001-07-10

Publication date

2002-01-17

2000-07-11 Priority claimed from US09/614,124 external-priority patent/US6630574B1/en

2000-08-29 Priority claimed from US09/651,563 external-priority patent/US6914132B1/en

2000-09-08 Priority claimed from US09/658,824 external-priority patent/US6746846B1/en

2000-09-26 Priority claimed from US09/671,325 external-priority patent/US6667154B1/en

2000-10-30 Priority claimed from US09/702,705 external-priority patent/US6504010B1/en

2000-12-13 Priority claimed from US09/736,457 external-priority patent/US6509448B2/en

2001-05-03 Priority claimed from US09/849,626 external-priority patent/US20020197669A1/en

2001-07-10 Application filed by Individual filed Critical Individual

2002-01-17 Publication of CA2415544A1 publication Critical patent/CA2415544A1/en

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 160
239000000203 mixture Substances 0.000 title claims abstract description 108
208000020816 lung neoplasm Diseases 0.000 title claims abstract description 37
206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 25
201000005202 lung cancer Diseases 0.000 title claims abstract description 25
238000003745 diagnosis Methods 0.000 title abstract description 10
238000002560 therapeutic procedure Methods 0.000 title abstract description 10
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 431
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 382
229920001184 polypeptide Polymers 0.000 claims abstract description 371
102000040430 polynucleotide Human genes 0.000 claims abstract description 162
108091033319 polynucleotide Proteins 0.000 claims abstract description 162
239000002157 polynucleotide Substances 0.000 claims abstract description 162
210000004027 cell Anatomy 0.000 claims abstract description 127
206010028980 Neoplasm Diseases 0.000 claims abstract description 109
210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 70
201000011510 cancer Diseases 0.000 claims abstract description 53
210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 31
238000011282 treatment Methods 0.000 claims abstract description 13
125000003275 alpha amino acid group Chemical group 0.000 claims description 166
108090000623 proteins and genes Proteins 0.000 claims description 145
102000004169 proteins and genes Human genes 0.000 claims description 93
230000027455 binding Effects 0.000 claims description 69
239000000427 antigen Substances 0.000 claims description 62
108091007433 antigens Proteins 0.000 claims description 62
102000036639 antigens Human genes 0.000 claims description 62
239000011230 binding agent Substances 0.000 claims description 54
230000014509 gene expression Effects 0.000 claims description 54
239000012634 fragment Substances 0.000 claims description 48
239000000523 sample Substances 0.000 claims description 48
230000000295 complement effect Effects 0.000 claims description 32
108091034117 Oligonucleotide Proteins 0.000 claims description 28
239000013604 expression vector Substances 0.000 claims description 25
239000012472 biological sample Substances 0.000 claims description 24
238000001514 detection method Methods 0.000 claims description 22
102000037865 fusion proteins Human genes 0.000 claims description 16
108020001507 fusion proteins Proteins 0.000 claims description 16
230000028993 immune response Effects 0.000 claims description 14
125000006853 reporter group Chemical group 0.000 claims description 13
239000003153 chemical reaction reagent Substances 0.000 claims description 11
238000011161 development Methods 0.000 claims description 10
230000002401 inhibitory effect Effects 0.000 claims description 10
230000000638 stimulation Effects 0.000 claims description 10
230000003308 immunostimulating effect Effects 0.000 claims description 9
239000000969 carrier Substances 0.000 claims description 8
229960001438 immunostimulant agent Drugs 0.000 claims description 8
239000003022 immunostimulating agent Substances 0.000 claims description 8
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 6
238000009007 Diagnostic Kit Methods 0.000 claims description 4
230000004936 stimulating effect Effects 0.000 claims description 4
230000002163 immunogen Effects 0.000 abstract description 47
201000010099 disease Diseases 0.000 abstract description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 17
208000037841 lung tumor Diseases 0.000 abstract description 12
230000002265 prevention Effects 0.000 abstract description 3
239000002299 complementary DNA Substances 0.000 description 834
235000018102 proteins Nutrition 0.000 description 88
108091028043 Nucleic acid sequence Proteins 0.000 description 65
239000013598 vector Substances 0.000 description 53
108020004414 DNA Proteins 0.000 description 49
235000001014 amino acid Nutrition 0.000 description 47
229940024606 amino acid Drugs 0.000 description 45
150000001413 amino acids Chemical class 0.000 description 45
239000013615 primer Substances 0.000 description 43
108091032973 (ribonucleotides)n+m Proteins 0.000 description 39
230000004927 fusion Effects 0.000 description 39
150000007523 nucleic acids Chemical group 0.000 description 39
125000000539 amino acid group Chemical group 0.000 description 37
239000008194 pharmaceutical composition Substances 0.000 description 32
239000003795 chemical substances by application Substances 0.000 description 31
102000039446 nucleic acids Human genes 0.000 description 30
108020004707 nucleic acids Proteins 0.000 description 30
239000002671 adjuvant Substances 0.000 description 29
239000002773 nucleotide Substances 0.000 description 29
125000003729 nucleotide group Chemical group 0.000 description 28
241000282414 Homo sapiens Species 0.000 description 26
108091092562 ribozyme Proteins 0.000 description 25
108090000994 Catalytic RNA Proteins 0.000 description 24
102000053642 Catalytic RNA Human genes 0.000 description 24
108091008874 T cell receptors Proteins 0.000 description 24
125000005647 linker group Chemical group 0.000 description 24
108091026890 Coding region Proteins 0.000 description 23
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 22
230000003321 amplification Effects 0.000 description 22
238000003556 assay Methods 0.000 description 22
210000004443 dendritic cell Anatomy 0.000 description 22
238000009472 formulation Methods 0.000 description 22
238000009396 hybridization Methods 0.000 description 22
238000003199 nucleic acid amplification method Methods 0.000 description 22
229960005486 vaccine Drugs 0.000 description 21
238000013459 approach Methods 0.000 description 20
230000015572 biosynthetic process Effects 0.000 description 20
108091093037 Peptide nucleic acid Proteins 0.000 description 19
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 19
238000007792 addition Methods 0.000 description 19
238000012384 transportation and delivery Methods 0.000 description 19
-1 vaccines Substances 0.000 description 19
238000003786 synthesis reaction Methods 0.000 description 18
210000001519 tissue Anatomy 0.000 description 18
230000014616 translation Effects 0.000 description 17
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 16
150000001875 compounds Chemical class 0.000 description 16
108020004999 messenger RNA Proteins 0.000 description 16
238000012217 deletion Methods 0.000 description 15
230000037430 deletion Effects 0.000 description 15
239000003814 drug Substances 0.000 description 15
150000003839 salts Chemical class 0.000 description 15
238000006467 substitution reaction Methods 0.000 description 15
238000013519 translation Methods 0.000 description 15
241000700605 Viruses Species 0.000 description 14
230000001900 immune effect Effects 0.000 description 14
239000002245 particle Substances 0.000 description 14
238000000746 purification Methods 0.000 description 14
239000007787 solid Substances 0.000 description 14
239000000243 solution Substances 0.000 description 14
102000004127 Cytokines Human genes 0.000 description 13
108090000695 Cytokines Proteins 0.000 description 13
239000002502 liposome Substances 0.000 description 13
230000001225 therapeutic effect Effects 0.000 description 13
102000053602 DNA Human genes 0.000 description 12
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 12
238000004458 analytical method Methods 0.000 description 12
230000000694 effects Effects 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 12
210000004379 membrane Anatomy 0.000 description 12
239000012528 membrane Substances 0.000 description 12
230000008569 process Effects 0.000 description 12
230000004044 response Effects 0.000 description 12
239000000126 substance Substances 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
108060003951 Immunoglobulin Proteins 0.000 description 11
230000000692 anti-sense effect Effects 0.000 description 11
230000002255 enzymatic effect Effects 0.000 description 11
102000018358 immunoglobulin Human genes 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
238000002741 site-directed mutagenesis Methods 0.000 description 11
238000013518 transcription Methods 0.000 description 11
230000035897 transcription Effects 0.000 description 11
210000004881 tumor cell Anatomy 0.000 description 11
239000002253 acid Substances 0.000 description 10
230000001965 increasing effect Effects 0.000 description 10
230000003993 interaction Effects 0.000 description 10
239000003550 marker Substances 0.000 description 10
230000004048 modification Effects 0.000 description 10
238000012986 modification Methods 0.000 description 10
230000036961 partial effect Effects 0.000 description 10
239000000758 substrate Substances 0.000 description 10
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 9
238000009169 immunotherapy Methods 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
239000000047 product Substances 0.000 description 9
238000010561 standard procedure Methods 0.000 description 9
239000003981 vehicle Substances 0.000 description 9
230000003612 virological effect Effects 0.000 description 9
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
108700026244 Open Reading Frames Proteins 0.000 description 8
239000000074 antisense oligonucleotide Substances 0.000 description 8
238000012230 antisense oligonucleotides Methods 0.000 description 8
230000001580 bacterial effect Effects 0.000 description 8
239000002585 base Substances 0.000 description 8
238000003776 cleavage reaction Methods 0.000 description 8
230000018109 developmental process Effects 0.000 description 8
239000012636 effector Substances 0.000 description 8
239000003623 enhancer Substances 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
239000002987 primer (paints) Substances 0.000 description 8
230000035755 proliferation Effects 0.000 description 8
230000009257 reactivity Effects 0.000 description 8
230000007017 scission Effects 0.000 description 8
238000012360 testing method Methods 0.000 description 8
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
238000010367 cloning Methods 0.000 description 7
230000001419 dependent effect Effects 0.000 description 7
229940079593 drug Drugs 0.000 description 7
238000005516 engineering process Methods 0.000 description 7
230000005847 immunogenicity Effects 0.000 description 7
230000001939 inductive effect Effects 0.000 description 7
210000004962 mammalian cell Anatomy 0.000 description 7
239000000463 material Substances 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
229920000056 polyoxyethylene ether Polymers 0.000 description 7
229930182490 saponin Natural products 0.000 description 7
235000017709 saponins Nutrition 0.000 description 7
150000007949 saponins Chemical class 0.000 description 7
241000701161 unidentified adenovirus Species 0.000 description 7
108020000948 Antisense Oligonucleotides Proteins 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
239000004471 Glycine Substances 0.000 description 6
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
239000004472 Lysine Substances 0.000 description 6
108020004511 Recombinant DNA Proteins 0.000 description 6
241000283984 Rodentia Species 0.000 description 6
206010046865 Vaccinia virus infection Diseases 0.000 description 6
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
150000007513 acids Chemical class 0.000 description 6
210000003719 b-lymphocyte Anatomy 0.000 description 6
230000001186 cumulative effect Effects 0.000 description 6
239000003937 drug carrier Substances 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
230000006870 function Effects 0.000 description 6
238000001415 gene therapy Methods 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
238000007918 intramuscular administration Methods 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
239000007788 liquid Substances 0.000 description 6
238000010369 molecular cloning Methods 0.000 description 6
230000035772 mutation Effects 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
238000012552 review Methods 0.000 description 6
241000894007 species Species 0.000 description 6
239000003826 tablet Substances 0.000 description 6
238000001890 transfection Methods 0.000 description 6
208000007089 vaccinia Diseases 0.000 description 6
239000004475 Arginine Substances 0.000 description 5
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
108020004705 Codon Proteins 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 5
108010002350 Interleukin-2 Proteins 0.000 description 5
102000000588 Interleukin-2 Human genes 0.000 description 5
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
108091081024 Start codon Proteins 0.000 description 5
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
239000004473 Threonine Substances 0.000 description 5
241000700618 Vaccinia virus Species 0.000 description 5
230000004913 activation Effects 0.000 description 5
125000000217 alkyl group Chemical group 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
229960001230 asparagine Drugs 0.000 description 5
235000009582 asparagine Nutrition 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004899 c-terminal region Anatomy 0.000 description 5
230000008859 change Effects 0.000 description 5
238000000576 coating method Methods 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
230000001976 improved effect Effects 0.000 description 5
230000006698 induction Effects 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
239000004005 microsphere Substances 0.000 description 5
210000001616 monocyte Anatomy 0.000 description 5
210000005259 peripheral blood Anatomy 0.000 description 5
239000011886 peripheral blood Substances 0.000 description 5
229920001282 polysaccharide Polymers 0.000 description 5
239000005017 polysaccharide Substances 0.000 description 5
150000004804 polysaccharides Chemical class 0.000 description 5
238000012545 processing Methods 0.000 description 5
230000006798 recombination Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
238000007920 subcutaneous administration Methods 0.000 description 5
239000000725 suspension Substances 0.000 description 5
230000009258 tissue cross reactivity Effects 0.000 description 5
238000011269 treatment regimen Methods 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
241000196324 Embryophyta Species 0.000 description 4
108091060211 Expressed sequence tag Proteins 0.000 description 4
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
102000006601 Thymidine Kinase Human genes 0.000 description 4
108020004440 Thymidine kinase Proteins 0.000 description 4
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
230000009471 action Effects 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
229960003767 alanine Drugs 0.000 description 4
235000004279 alanine Nutrition 0.000 description 4
230000000259 anti-tumor effect Effects 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000011575 calcium Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
238000013461 design Methods 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
238000010494 dissociation reaction Methods 0.000 description 4
230000005593 dissociations Effects 0.000 description 4
239000012530 fluid Substances 0.000 description 4
238000001476 gene delivery Methods 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
230000012010 growth Effects 0.000 description 4
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
239000000833 heterodimer Substances 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
238000003018 immunoassay Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
230000002452 interceptive effect Effects 0.000 description 4
229960000310 isoleucine Drugs 0.000 description 4
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
238000002372 labelling Methods 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
244000005700 microbiome Species 0.000 description 4
238000012544 monitoring process Methods 0.000 description 4
229940035032 monophosphoryl lipid a Drugs 0.000 description 4
238000002703 mutagenesis Methods 0.000 description 4
231100000350 mutagenesis Toxicity 0.000 description 4
239000002088 nanocapsule Substances 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
238000010647 peptide synthesis reaction Methods 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
229940051841 polyoxyethylene ether Drugs 0.000 description 4
239000000843 powder Substances 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
238000012216 screening Methods 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
238000001179 sorption measurement Methods 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
239000004474 valine Substances 0.000 description 4
108700028369 Alleles Proteins 0.000 description 3
241000271566 Aves Species 0.000 description 3
241000700663 Avipoxvirus Species 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
241000759568 Corixa Species 0.000 description 3
102100031725 Cortactin-binding protein 2 Human genes 0.000 description 3
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
101710177611 DNA polymerase II large subunit Proteins 0.000 description 3
101710184669 DNA polymerase II small subunit Proteins 0.000 description 3
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 3
108010013369 Enteropeptidase Proteins 0.000 description 3
102100029727 Enteropeptidase Human genes 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
102000005720 Glutathione transferase Human genes 0.000 description 3
108010070675 Glutathione transferase Proteins 0.000 description 3
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
108091027305 Heteroduplex Proteins 0.000 description 3
108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 3
108091092195 Intron Proteins 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
101710182846 Polyhedrin Proteins 0.000 description 3
101710197985 Probable protein Rev Proteins 0.000 description 3
206010036790 Productive cough Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
101710188053 Protein D Proteins 0.000 description 3
101710132893 Resolvase Proteins 0.000 description 3
206010041067 Small cell lung cancer Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000005867 T cell response Effects 0.000 description 3
108700012920 TNF Proteins 0.000 description 3
241000723873 Tobacco mosaic virus Species 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
229940009098 aspartate Drugs 0.000 description 3
239000011324 bead Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
230000001461 cytolytic effect Effects 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
239000007789 gas Substances 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
229930195712 glutamate Natural products 0.000 description 3
230000013595 glycosylation Effects 0.000 description 3
238000006206 glycosylation reaction Methods 0.000 description 3
230000028996 humoral immune response Effects 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
230000007774 longterm Effects 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
239000011859 microparticle Substances 0.000 description 3
201000000050 myeloid neoplasm Diseases 0.000 description 3
239000007764 o/w emulsion Substances 0.000 description 3
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
239000006187 pill Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
238000001243 protein synthesis Methods 0.000 description 3
150000003212 purines Chemical group 0.000 description 3
239000001397 quillaja saponaria molina bark Substances 0.000 description 3
230000008707 rearrangement Effects 0.000 description 3
238000010188 recombinant method Methods 0.000 description 3
238000005215 recombination Methods 0.000 description 3
238000011084 recovery Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
208000024794 sputum Diseases 0.000 description 3
210000003802 sputum Anatomy 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000002194 synthesizing effect Effects 0.000 description 3
239000011732 tocopherol Substances 0.000 description 3
229960001295 tocopherol Drugs 0.000 description 3
229930003799 tocopherol Natural products 0.000 description 3
235000010384 tocopherol Nutrition 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
108700023418 Amidases Proteins 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
101710132601 Capsid protein Proteins 0.000 description 2
241001227713 Chiron Species 0.000 description 2
108700010070 Codon Usage Proteins 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
206010014611 Encephalitis venezuelan equine Diseases 0.000 description 2
108010074860 Factor Xa Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
208000000666 Fowlpox Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
108091027874 Group I catalytic intron Proteins 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
108010065805 Interleukin-12 Proteins 0.000 description 2
102000013462 Interleukin-12 Human genes 0.000 description 2
102000004388 Interleukin-4 Human genes 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical class [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
108010047702 MPG peptide Proteins 0.000 description 2
241000187479 Mycobacterium tuberculosis Species 0.000 description 2
102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 2
241000221960 Neurospora Species 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
108091005461 Nucleic proteins Proteins 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
241000220317 Rosa Species 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
241000251131 Sphyrna Species 0.000 description 2
241000256251 Spodoptera frugiperda Species 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
241000255985 Trichoplusia Species 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 2
201000009145 Venezuelan equine encephalitis Diseases 0.000 description 2
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
229940024545 aluminum hydroxide Drugs 0.000 description 2
102000005922 amidase Human genes 0.000 description 2
150000001412 amines Chemical group 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
229960000074 biopharmaceutical Drugs 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
210000004900 c-terminal fragment Anatomy 0.000 description 2
150000001720 carbohydrates Chemical group 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000007123 defense Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000000551 dentifrice Substances 0.000 description 2
UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 2
UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 2
230000003292 diminished effect Effects 0.000 description 2
239000002612 dispersion medium Substances 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
229940011399 escin Drugs 0.000 description 2
210000004700 fetal blood Anatomy 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
229940127121 immunoconjugate Drugs 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000036512 infertility Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
238000007689 inspection Methods 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
239000003446 ligand Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
238000011068 loading method Methods 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000006249 magnetic particle Substances 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
238000007899 nucleic acid hybridization Methods 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
244000052769 pathogen Species 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
239000012071 phase Substances 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000004800 polyvinyl chloride Substances 0.000 description 2
229920000915 polyvinyl chloride Polymers 0.000 description 2
230000001323 posttranslational effect Effects 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
235000007686 potassium Nutrition 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000010076 replication Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
239000006152 selective media Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
230000008685 targeting Effects 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical compound NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
239000013607 AAV vector Substances 0.000 description 1
108010066676 Abrin Proteins 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010025188 Alcohol oxidase Proteins 0.000 description 1
241000710929 Alphavirus Species 0.000 description 1
241000024188 Andala Species 0.000 description 1
102000006306 Antigen Receptors Human genes 0.000 description 1
108010083359 Antigen Receptors Proteins 0.000 description 1
241000272478 Aquila Species 0.000 description 1
101100365013 Arabidopsis thaliana SCL3 gene Proteins 0.000 description 1
101100365014 Arabidopsis thaliana SCL4 gene Proteins 0.000 description 1
101100043743 Arabidopsis thaliana STY8 gene Proteins 0.000 description 1
241000239290 Araneae Species 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
102100032306 Aurora kinase B Human genes 0.000 description 1
108090000749 Aurora kinase B Proteins 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
241000283725 Bos Species 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
108010029697 CD40 Ligand Proteins 0.000 description 1
101150013553 CD40 gene Proteins 0.000 description 1
102100032937 CD40 ligand Human genes 0.000 description 1
101100365877 Caenorhabditis elegans cdl-1 gene Proteins 0.000 description 1
101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 1
241000178270 Canarypox virus Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241000701489 Cauliflower mosaic virus Species 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
240000006162 Chenopodium quinoa Species 0.000 description 1
235000015493 Chenopodium quinoa Nutrition 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
239000005496 Chlorsulfuron Substances 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
102000000989 Complement System Proteins Human genes 0.000 description 1
108010069112 Complement System Proteins Proteins 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
108091029430 CpG site Proteins 0.000 description 1
108050006400 Cyclin Proteins 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108010024212 E-Selectin Proteins 0.000 description 1
102100023471 E-selectin Human genes 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
241001524679 Escherichia virus M13 Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
241000700662 Fowlpox virus Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102000027484 GABAA receptors Human genes 0.000 description 1
108091008681 GABAA receptors Proteins 0.000 description 1
108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
102000053187 Glucuronidase Human genes 0.000 description 1
108010060309 Glucuronidase Proteins 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
241001316290 Gypsophila Species 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
101000590482 Homo sapiens Kinetochore protein Nuf2 Proteins 0.000 description 1
101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 description 1
101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
102000003816 Interleukin-13 Human genes 0.000 description 1
108090000176 Interleukin-13 Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
102100021592 Interleukin-7 Human genes 0.000 description 1
101150008942 J gene Proteins 0.000 description 1
125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
125000000773 L-serino group Chemical group [H]OC(=O)[C@@]([H])(N([H])*)C([H])([H])O[H] 0.000 description 1
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108010031099 Mannose Receptor Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
206010048723 Multiple-drug resistance Diseases 0.000 description 1
MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
241000238367 Mya arenaria Species 0.000 description 1
241000187488 Mycobacterium sp. Species 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
KTHDTJVBEPMMGL-VKHMYHEASA-N N-acetyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(C)=O KTHDTJVBEPMMGL-VKHMYHEASA-N 0.000 description 1
KTHDTJVBEPMMGL-UHFFFAOYSA-N N-acetyl-L-alanine Natural products OC(=O)C(C)NC(C)=O KTHDTJVBEPMMGL-UHFFFAOYSA-N 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
101710087110 ORF6 protein Proteins 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
108010013639 Peptidoglycan Proteins 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
102100040307 Protein FAM3B Human genes 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 1
108010066717 Q beta Replicase Proteins 0.000 description 1
108010013845 RNA Polymerase I Proteins 0.000 description 1
102000017143 RNA Polymerase I Human genes 0.000 description 1
108010009460 RNA Polymerase II Proteins 0.000 description 1
102000009572 RNA Polymerase II Human genes 0.000 description 1
108010078067 RNA Polymerase III Proteins 0.000 description 1
102000014450 RNA Polymerase III Human genes 0.000 description 1
108020004518 RNA Probes Proteins 0.000 description 1
239000003391 RNA probe Substances 0.000 description 1
230000007022 RNA scission Effects 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
238000010240 RT-PCR analysis Methods 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
101150075681 SCL1 gene Proteins 0.000 description 1
241000710961 Semliki Forest virus Species 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
108010079723 Shiga Toxin Proteins 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
241000710960 Sindbis virus Species 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
102100036407 Thioredoxin Human genes 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
101710198378 Uncharacterized 10.8 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
101710134973 Uncharacterized 9.7 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 1
101150117115 V gene Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000003082 abrasive agent Substances 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
108020002494 acetyltransferase Proteins 0.000 description 1
102000005421 acetyltransferase Human genes 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
125000003172 aldehyde group Chemical group 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
239000012637 allosteric effector Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940037003 alum Drugs 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
229940024546 aluminum hydroxide gel Drugs 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
235000010208 anthocyanin Nutrition 0.000 description 1
229930002877 anthocyanin Natural products 0.000 description 1
239000004410 anthocyanin Substances 0.000 description 1
150000004636 anthocyanins Chemical class 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000005809 anti-tumor immunity Effects 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000005975 antitumor immune response Effects 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000002820 assay format Methods 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
230000037429 base substitution Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000000227 bioadhesive Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000008827 biological function Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
229950004398 broxuridine Drugs 0.000 description 1
229940046011 buccal tablet Drugs 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
238000002619 cancer immunotherapy Methods 0.000 description 1
239000012830 cancer therapeutic Substances 0.000 description 1
238000001818 capillary gel electrophoresis Methods 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
230000021523 carboxylation Effects 0.000 description 1
238000006473 carboxylation reaction Methods 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
108020001778 catalytic domains Proteins 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000012832 cell culture technique Methods 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013522 chelant Substances 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
238000012926 crystallographic analysis Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
101150047356 dec-1 gene Proteins 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
210000001787 dendrite Anatomy 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
229930186222 escin Natural products 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000001808 exosome Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000011152 fibreglass Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
108700014844 flt3 ligand Proteins 0.000 description 1
239000004088 foaming agent Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
230000002363 herbicidal effect Effects 0.000 description 1
239000004009 herbicide Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
101150113423 hisD gene Proteins 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
239000003906 humectant Substances 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000012642 immune effector Substances 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
208000037798 influenza B Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000002743 insertional mutagenesis Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000007852 inverse PCR Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
238000002955 isolation Methods 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
238000005304 joining Methods 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000002523 lectin Substances 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
238000007834 ligase chain reaction Methods 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
230000029226 lipidation Effects 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229910044991 metal oxide Inorganic materials 0.000 description 1
150000004706 metal oxides Chemical class 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
238000002493 microarray Methods 0.000 description 1
238000010208 microarray analysis Methods 0.000 description 1
238000012775 microarray technology Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
239000000178 monomer Substances 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
229940051866 mouthwash Drugs 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
238000001821 nucleic acid purification Methods 0.000 description 1
238000001668 nucleic acid synthesis Methods 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
230000030648 nucleus localization Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
238000005457 optimization Methods 0.000 description 1
229940100688 oral solution Drugs 0.000 description 1
239000000668 oral spray Substances 0.000 description 1
229940041678 oral spray Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
150000004633 phorbol derivatives Chemical class 0.000 description 1
239000002644 phorbol ester Substances 0.000 description 1
150000004713 phosphodiesters Chemical group 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229940023488 pill Drugs 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
108700028325 pokeweed antiviral Proteins 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920002851 polycationic polymer Polymers 0.000 description 1
230000000379 polymerizing effect Effects 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940116317 potato starch Drugs 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
238000007639 printing Methods 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000003439 radiotherapeutic effect Effects 0.000 description 1
230000000601 reactogenic effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
230000035939 shock Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
108060008226 thioredoxin Proteins 0.000 description 1
229940094937 thioredoxin Drugs 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
238000012090 tissue culture technique Methods 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000006276 transfer reaction Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
101150081616 trpB gene Proteins 0.000 description 1
101150111232 trpB-1 gene Proteins 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
150000003668 tyrosines Chemical class 0.000 description 1
239000011882 ultra-fine particle Substances 0.000 description 1
231100000402 unacceptable toxicity Toxicity 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000009637 wintergreen oil Substances 0.000 description 1
QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1
QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
239000011701 zinc Chemical class 0.000 description 1
229910052725 zinc Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Cell Biology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA002415544A 2000-07-11 2001-07-10 Compositions and methods for the therapy and diagnosis of lung cancer Abandoned CA2415544A1 (en)

Applications Claiming Priority (17)

Application Number	Priority Date	Filing Date	Title
US09/614,124		2000-07-11
US09/614,124 US6630574B1 (en)	1999-06-30	2000-07-11	Compositions and methods for the therapy and diagnosis of lung cancer
US09/651,563 US6914132B1 (en)	1999-06-30	2000-08-29	Compositions and methods for the therapy and diagnosis of lung cancer
US09/651,563		2000-08-29
US09/658,824 US6746846B1 (en)	1999-06-30	2000-09-08	Methods for diagnosing lung cancer
US09/658,824		2000-09-08
US09/671,325 US6667154B1 (en)	1999-06-30	2000-09-26	Compositions and methods for the therapy and diagnosis of lung cancer
US09/671,325		2000-09-26
US67741900A	2000-10-06	2000-10-06
US09/677,419		2000-10-06
US09/702,705 US6504010B1 (en)	1999-06-30	2000-10-30	Compositions and methods for the therapy and diagnosis of lung cancer
US09/702,705		2000-10-30
US09/736,457		2000-12-13
US09/736,457 US6509448B2 (en)	1999-06-30	2000-12-13	Compositions and methods for the therapy and diagnosis of lung cancer
US09/849,626 US20020197669A1 (en)	2000-12-13	2001-05-03	Compositions and methods for the therapy and diagnosis of lung cancer
US09/849,626		2001-05-03
PCT/US2001/022058 WO2002004514A2 (en)	2000-07-11	2001-07-10	Compositions and methods for the therapy and diagnosis of lung cancer

Publications (1)

Publication Number	Publication Date
CA2415544A1 true CA2415544A1 (en)	2002-01-17

Family

ID=27575493

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002415544A Abandoned CA2415544A1 (en)	2000-07-11	2001-07-10	Compositions and methods for the therapy and diagnosis of lung cancer

Country Status (6)

Country	Link
EP (1)	EP1343886A2 (ja)
JP (1)	JP2004512824A (ja)
AR (1)	AR031250A1 (ja)
AU (1)	AU2002218770A1 (ja)
CA (1)	CA2415544A1 (ja)
WO (1)	WO2002004514A2 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030170255A1 (en) *	1999-06-30	2003-09-11	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en)	1999-06-30	2003-11-13	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
US6893818B1 (en)	1999-10-28	2005-05-17	Agensys, Inc.	Gene upregulated in cancers of the prostate
CA2490853A1 (en) *	1999-12-01	2001-06-07	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030166300A1 (en) *	2000-08-30	2003-09-04	Tang Y. Tom	Growth-related inflammatory and immune response protein
ZA200204907B (en)	2001-06-26	2003-03-03	Univ Nat Taiwan	Collapsin Response Mediator Protein-1.
US20060242721A1 (en) *	2002-08-14	2006-10-26	Sang-Seok Koh	Gene families associated with liver cancer
AU2003263045A1 (en) *	2002-09-26	2004-04-19	Genentech, Inc.	Novel compositions and methods for the treatment of psoriasis
TW200413725A (en) *	2002-09-30	2004-08-01	Oncotherapy Science Inc	Method for diagnosing non-small cell lung cancers
US7449291B1 (en)	2003-01-13	2008-11-11	University Of Washington	Methods for identifying subjects susceptible to Charcot-Marie-Tooth neuropathy type 1C
WO2004070058A1 (en) *	2003-02-03	2004-08-19	Bayer Healthcare Ag	Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of copd
AU2004224448A1 (en) *	2003-03-24	2004-10-07	Corixa Corporation	Detection and monitoring of lung cancer
US20080153104A1 (en)	2003-08-08	2008-06-26	Hiroyuki Aburantai	Gene Overexpressed in Cancer
TW200512298A (en)	2003-09-24	2005-04-01	Oncotherapy Science Inc	Method of diagnosing breast cancer
JP4428995B2 (ja)	2003-12-03	2010-03-10	関東化学株式会社	金属膜のエッチング液組成物
WO2006131783A2 (en) *	2004-01-27	2006-12-14	Compugen Usa, Inc.	Polynucleotides, polypeptides, and diagnosing lung cancer
US20050186577A1 (en)	2004-02-20	2005-08-25	Yixin Wang	Breast cancer prognostics
US8940488B2 (en)	2004-03-31	2015-01-27	Hiroyuki Aburatani	Cancer diagnosis and treatment of cancer using anti-robo 1 antibody
WO2005095981A1 (ja)	2004-03-31	2005-10-13	Perseus Proteomics Inc.	抗robo1抗体を用いる癌の診断および治療
US7943295B2 (en) *	2005-07-29	2011-05-17	Oncotherapy Science, Inc.	Screening and therapeutic method for NSCLC targeting CDCA1-KNTC2 complex
US20110038849A1 (en) *	2006-12-21	2011-02-17	Intradigm Corporation	Inhibitory polynucleotide compositions and methods for treating cancer
JP5117765B2 (ja)	2007-05-28	2013-01-16	国立大学法人東京大学	抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
BRPI0815578B8 (pt) *	2007-08-20	2023-01-03	Oncotherapy Science Inc	Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
TWI526219B (zh)	2008-06-19	2016-03-21	腫瘤療法科學股份有限公司	Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
EP2433964A4 (en) *	2009-05-22	2013-09-11	Univ Okayama Nat Univ Corp	PEPTIDE INDUCING SPECIFIC IMMUNE RESPONSE AGAINST XAGE-1B AND USE THEREOF
EP2872532A4 (en)	2012-07-10	2016-04-13	Oncotherapy Science Inc	CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH
CN114102955B (zh) *	2020-08-31	2024-05-07	天津科技大学	一种采用常温发泡技术制备发泡聚乳酸的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH10139800A (ja) *	1996-11-15	1998-05-26	Santen Pharmaceut Co Ltd	シェーグレン症候群治療剤
ID27813A (id) *	1998-01-28	2001-04-26	Corixa Corp	Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
AU3899700A (en) *	1999-03-17	2000-10-04	Alphagene, Inc.	Secreted proteins and polynucleotides encoding them
AR032743A1 (es) *	1999-06-30	2003-11-26	Corixa Corp	Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon

2001
- 2001-07-10 CA CA002415544A patent/CA2415544A1/en not_active Abandoned
- 2001-07-10 EP EP01984164A patent/EP1343886A2/en not_active Withdrawn
- 2001-07-10 WO PCT/US2001/022058 patent/WO2002004514A2/en active Application Filing
- 2001-07-10 AU AU2002218770A patent/AU2002218770A1/en not_active Abandoned
- 2001-07-10 AR ARP010103274A patent/AR031250A1/es unknown
- 2001-07-10 JP JP2002509377A patent/JP2004512824A/ja active Pending

Also Published As

Publication number	Publication date
EP1343886A2 (en)	2003-09-17
JP2004512824A (ja)	2004-04-30
AU2002218770A1 (en)	2002-01-21
WO2002004514A3 (en)	2003-06-19
WO2002004514A2 (en)	2002-01-17
AR031250A1 (es)	2003-09-17
WO2002004514A8 (en)	2002-12-27

Publication	Publication Date	Title
US6858710B2 (en)	2005-02-22	Compositions and methods for the therapy and diagnosis of ovarian cancer
US7425607B2 (en)	2008-09-16	Compositions comprising a lung tumor antigen
US6504010B1 (en)	2003-01-07	Compositions and methods for the therapy and diagnosis of lung cancer
US20080317755A1 (en)	2008-12-25	Compositions and methods for the therapy and diagnosis of colon cancer
CA2415544A1 (en)	2002-01-17	Compositions and methods for the therapy and diagnosis of lung cancer
CA2412223A1 (en)	2001-12-20	Compositions and methods for the therapy and diagnosis of colon cancer
EP1287029A2 (en)	2003-03-05	Compositions and methods for the therapy and diagnosis of colon cancer
US6509448B2 (en)	2003-01-21	Compositions and methods for the therapy and diagnosis of lung cancer
US20020172952A1 (en)	2002-11-21	Compositions and methods for the therapy and diagnosis of lung cancer
US6858204B2 (en)	2005-02-22	Compositions and methods for the therapy and diagnosis of lung cancer
WO2002074237A2 (en)	2002-09-26	Compositions and methods for the therapy and diagnosis of kidney cancer
US20070292415A1 (en)	2007-12-20	Compositions and methods for the therapy and diagnosis of breast cancer
US20030170255A1 (en)	2003-09-11	Compositions and methods for the therapy and diagnosis of lung cancer
US20020150922A1 (en)	2002-10-17	Compositions and methods for the therapy and diagnosis of colon cancer
US20020197669A1 (en)	2002-12-26	Compositions and methods for the therapy and diagnosis of lung cancer
US7888477B2 (en)	2011-02-15	Ovarian cancer-associated antibodies and kits
US20030069180A1 (en)	2003-04-10	Compositions and methods for the therapy and diagnosis of colon cancer
CA2437564A1 (en)	2002-08-15	Compositions and methods for the therapy and diagnosis of breast cancer
WO2001096389A2 (en)	2001-12-20	Compositions and methods for the therapy and diagnosis of colon cancer
US20020131971A1 (en)	2002-09-19	Compositions and methods for the therapy and diagnosis of colon cancer
US20110177082A1 (en)	2011-07-21	Compositions and methods for the therapy and diagnosis of ovarian cancer
US20020156011A1 (en)	2002-10-24	Compositions and methods for the therapy and diagnosis of colon cancer

Legal Events

Date	Code	Title	Description
2006-07-10	EEER	Examination request
2010-07-12	FZDE	Discontinued